Previous Article | Next Article ![]()
Infection and Immunity, January 2004, p. 589-592, Vol. 72, No. 1
0019-9567/04/$08.00+0 DOI: 10.1128/IAI.72.1.589-592.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Weill Medical College of Cornell University,1 Department of Medical and Molecular Parasitology, New York University School of Medicine, New York,3 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York2
Received 20 June 2003/ Accepted 16 August 2003
|
|
|---|
|
|
|---|
The CD1 family consists of nonpolymorphic antigen-presenting molecules that are expressed on antigen-presenting cells and induced on peripheral blood monocytes (PBMs) by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF) and other cytokines (21, 23). Group I CD1 molecules, which include human CD1a, CD1b, and CD1c, have been shown to present mycobacterial lipids and glycolipids to specific T cells. These can potentially contribute to antimicrobial resistance by production of gamma interferon (IFN-
) (24) and the antimicrobial protein granulysin (27). The group I CD1 proteins are thus likely to be involved in the protective immune response against complex intracellular pathogens such as Leishmania species, which are know to harbor abundant glycolipid antigens.
Intracellular pathogens, however, have evolved various survival strategies to avoid immune recognition of infected host cells. These include down-regulation of antigen-presenting molecules by Mycobacterium and Leishmania (19, 28), capture and degradation of antigen-presenting molecules by Leishmania mexicana and Leishmania amazonensis amastigotes (1), and interference with intracellular antigen-loading by Leishmania major promastigotes (10). Here we demonstrate that Leishmania donovani promastigotes block lipid antigen presentation in infected human DCs and down-regulate group I CD1 expression. Both processes may potentially be associated with the establishment of a disease-promoting immune response and chronic infection.
We tested in vitro the ability of Leishmania-infected dendritic cells (DCs) to present antigen to a well-characterized CD1b-restricted T-cell line (DN1) (17), which is specific for the mycobacterial lipid mycolic acid (4). Human blood monocytes were isolated from random donor leukocyte concentrates and differentiated to immature DCs by a 3-day incubation with GM-CSF (300 U/ml; Immunex Corporation, Seattle, Wash.) and interleukin 4 (IL-4; 200 U/ml; gift from Schering Corporation, Kenilworth, N.J.). Irradiated (5,000 rads) immature DCs were infected with stationary-phase L. donovani promastigotes (MHOM/SD/1S-2D, referred to as LD1S) at a multiplicity of 10 parasites per host cell, and infected cells as well as uninfected controls were incubated at a 1:1 ratio with DN1 T cells in the presence of 5 µg of Mycobacterium tuberculosis sonicate per ml. Uninfected DCs efficiently presented mycobacterial mycolic acids, as judged by incorporation of radiolabeled thymidine into proliferating activated T cells (Fig. 1A, top) and their robust secretion of IFN-
(middle). In contrast, infected DCs were unable to stimulate T-cell proliferation, and a substantial decrease in T-cell IFN-
production was observed. T cells were not activated by incubation with infected DCs alone or Leishmania sonicate (not shown), a result expected from the known specificity of the DN1 T-cell line to mycobacterial mycolic acid (4).
![]() View larger version (57K): [in a new window] |
FIG. 1. Leishmania-infected DCs inhibit CD1b-restricted T-cell activation. (A) T-cell proliferation and activation assay. L. donovani LD1S-infected DCs were incubated 2 days postinfection with CD1b-restricted T cells (DN1 cells) in the presence or absence of 5 µg of M. tuberculosis (Mtb) sonicate per ml, and proliferation (top) and cytokine secretion (middle) were assessed. At least three independent experiments with similar outcomes were performed, and triplicate values from one representative experiment are shown. (B) Immunofluorescence analysis. Infected human DCs were immobilized on poly-L-lysine-coated glass coverslips, fixed in 4% paraformaldehyde (left), or fixed and permeabilized with ice cold ethanol (right) and sequentially incubated with the monoclonal antiphosphoglycan antibody CA7AE and Texas red-conjugated anti-mouse immunoglobulin G secondary antibody. Host and parasite DNAs were counterstained with 0.5 µg of Hoechst 33342 per ml. Bar, 5 µm.
|
Since the ability of DCs to phagocytose Leishmania promastigotes in culture has been questioned (31), we confirmed that infection of DCs under the conditions used in our experiments led to intracellular parasitism. As determined by nuclear staining, 85 to 90% of DCs were generally infected in our experiments (Fig. 1B, top). Only a minor fraction of the parasites were associated with the host cell surface, as shown by immunofluorescence staining of nonpermeabilized DCs with antiphosphoglycan antibody CA7AE (29). More than 90% of the parasites were labeled only following host cell permeabilization, indicating predominant intracellular parasite localization.
We next tested if inhibition of the CD1-mediated responses was associated with transcriptional down-regulation of CD1 expression. Human DCs obtained from seven healthy random donors were infected with stationary-phase promastigotes as described above, and total RNA was isolated with Trizol reagent (Gibco BRL, Carlsbad, Calif.) 2 days after the infection. Abundance of CD1a, -b, and -c mRNA was determined by quantitative reverse transcription (RT)-PCR. Three distinct patterns of regulation were observed (Fig. 2A): two donors (donors 1 and 2) showed no or only moderate down-regulation of the three CD1 isoforms, two donors (donors 3 and 4) showed substantial inhibition of CD1 expression ranging from two- to fivefold, and three donors (donors 5, 6, and 7) showed strong down-regulation above 20-fold compared to the uninfected control. With the exception of donor 5, the level of inhibition was comparable between the three isoforms, suggesting a process of coordinate down-regulation of the genes. However, the overall heterogeneity of this phenomenon between the various donors suggests the presence of unknown host factors that determine susceptibility to CD1 down-regulation.
![]() View larger version (35K): [in a new window] |
FIG. 2. Leishmania-infected DCs down-regulate CD1 expression. (A) RT-PCR analysis. Infected DCs and uninfected controls from seven donors were cultured for 48 h, and total RNA was extracted. TaqMan one-step RT-PCR (Applied Biosystems) was carried out with the ABI Prism 7900HT apparatus (Perkin-Elmer). CD1a, -b, and -c specific primer oligonucleotides and an internal probe oligonucleotide labeled with both a reporter (VIC; Applied Biosystems) and a quencher dye (TAMRA; 6-carboxy-tetramethyl-rhodamine) were added to the RT-PCR mix at the beginning of the reaction. GAPDH (glyceraldehyde-3-phosphate dehydrogenase) mRNA levels were measured as an internal control with the human GAPDH TaqMan one-step kit (Applied Biosystems). Sequences for CD1 forward primers, reverse primers, and probes (respectively) were as follows: CD1A, 5'-ATCTCCAGCGGTCAAGTGAAG-3', 5'-ACACGGGCTTTGGGTAGAATC-3', and VIC-5'-CCTAGGCCTGGCTGTCCCATG-3'-TAMRA; CD1B, 5'-GGGTGAAGCACACAGCAGTTTAGA-3', 5'-CCAAACAATTGAGCCAATGG-3', and VIC-5'-AGGACATCATCTCTACTGGAGAAACCCCAC-3'-TAMRA; CD1C, 5'-GGGAGATTCAATACCATGCAA-3', 5'-CAGCCCGCTTTCACCTGTAC-3', and VIC-5'-TCAAGATTACTCGAAATATCCCTTTGA-3'-TAMRA. Inhibition of CD1 mRNA expression of the infected DCs relative to that of the uninfected DCs from the same donor is shown. *, no inhibition. Analysis was done in quadruplicate, and bars indicate standard deviations. (B) Flow cytometry. DCs obtained from six donors (left) were infected with stationary-phase LD1S promastigotes, and surface marker expression was assessed by flow cytometry. The inhibition of the mean fluorescence intensity relative to that of autologous uninfected DCs (percent) is shown. Stationary-phase, live promastigotes, heat-killed promastigotes, or 1-nm latex beads (Sigma) were incubated at 37°C at a 10:1 ratio with immature DCs (left). Surface marker expression was quantified 48 h later and compared to that in autologous uninfected controls. *, statistically significant difference relative to live-Leishmania-infected cells (P < 0.05). Statistical analysis was performed with the Mann-Whitney U test.
|
Visceral Leishmania heavily colonizes the bone marrow of the infected host, where it may interfere with the differentiation of immune effector cells. We therefore tested the effect of intracellular Leishmania on induction of CD1 expression during differentiation of PBMs into immature DCs. PBMs of three donors were infected with stationary-phase promastigotes and incubated for 3 days with GM-CSF-IL-4. Surface marker expression of CD1a, -b, and -c, as well as major histocompatibility complex (MHC) class I (using monoclonal antibody PA2.6 [(8]) and class II (using monoclonal antibody L243 [13]), was quantified thereafter by flow cytometry and compared to results for cytokine-treated uninfected controls. As expected, uninfected PBMs differentiated into immature DCs and induced expression of all three group I CD1 isoforms (Fig. 3, left). In contrast, PBMs showed markedly reduced induction of CD1a, -b, and -c expression if previously infected with Leishmania (Fig. 3, right). No effect of either cytokine-treatment or Leishmania infection on MHC class I and class II expression was observed.
![]() View larger version (47K): [in a new window] |
FIG. 3. Leishmania inhibits cytokine-induced CD1 expression in PBMs. (Left) Infected (open histograms) and uninfected (closed histograms) PBMs were incubated with GM-CSF and IL-4 and analyzed for group I CD1, MHC class I, and MHC class II expression by flow cytometry. The panel shows one representative histogram from three independent experiments performed. (Right) Percent reduction of cell surface expression in infected versus uninfected monocytes obtained from three donors. Data are averages, bars indicate standard deviations, and asterisks indicate that no inhibition was observed.
|
This work was supported by grants AI48933 and AI45889 from NIH/NIAID. J. Amprey was supported by NIH MSTP grant GM07739. G. Späth was supported by the Starr Foundation.
|
|
|---|
ß+ T cells. Nature 372:691-694.[CrossRef][Medline]
ß T cell pool. J. Immunol. 162:366-371.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»